BACKGROUND: Interleukin-6 (IL-6) is a multifunctional cytokine that plays roles in the immune response, inflammation and hematopoiesis. Serum IL-6 levels have reported to reflect disease severity and high tumor burden in multiple myeloma (MM) patients and to correlate with several other laboratory parameters. Serum-soluble IL-6 receptor (sIL-6R) plays an agonist role in IL-6 signaling, enhancing its biological activity tenfold. PURPOSE- METHODS: We measured IL-6 and sIL-6R levels in 11 patients (7 male, 4 female, mean age 66.9 yr) with Waldenström's macrobulinemia (WM) using a commercially available enzyme-linked immunoassay in order to investigate their biological role and to find any possible relationship with disease severity, tumor burden or response to treatment. RESULTS: Serum IL-6 and sIL-6R concentrations at diagnosis were significantly higher than in healthy controls (Mann Whitney U-test, p < 0.001 and p < 0.01, respectively). Patients who were effectively treated had a significant reduction in IL-6 levels (p = 0.017). With regard to sIL-6R levels, no specific tendency was observed. In some of the responsive patients the levels increased whereas in others they decreased. No correlation was found between IL-6 and sIL-6R levels at diagnosis (p = 0.9, r = 0.036) or after treatment (p = 0.083, r = 0.3). CONCLUSIONS: Our results suggest that IL-6 may be a marker reflecting tumor burden, disease severity and response to treatment in WM. With regard to sIL-6R, we believe that it does not seem to be of much value, and its role remains to be clarified. However, future studies are needed to confirm and further extend the present results.
BACKGROUND:Interleukin-6 (IL-6) is a multifunctional cytokine that plays roles in the immune response, inflammation and hematopoiesis. Serum IL-6 levels have reported to reflect disease severity and high tumor burden in multiple myeloma (MM) patients and to correlate with several other laboratory parameters. Serum-soluble IL-6 receptor (sIL-6R) plays an agonist role in IL-6 signaling, enhancing its biological activity tenfold. PURPOSE- METHODS: We measured IL-6 and sIL-6R levels in 11 patients (7 male, 4 female, mean age 66.9 yr) with Waldenström's macrobulinemia (WM) using a commercially available enzyme-linked immunoassay in order to investigate their biological role and to find any possible relationship with disease severity, tumor burden or response to treatment. RESULTS: Serum IL-6 and sIL-6R concentrations at diagnosis were significantly higher than in healthy controls (Mann Whitney U-test, p < 0.001 and p < 0.01, respectively). Patients who were effectively treated had a significant reduction in IL-6 levels (p = 0.017). With regard to sIL-6R levels, no specific tendency was observed. In some of the responsive patients the levels increased whereas in others they decreased. No correlation was found between IL-6 and sIL-6R levels at diagnosis (p = 0.9, r = 0.036) or after treatment (p = 0.083, r = 0.3). CONCLUSIONS: Our results suggest that IL-6 may be a marker reflecting tumor burden, disease severity and response to treatment in WM. With regard to sIL-6R, we believe that it does not seem to be of much value, and its role remains to be clarified. However, future studies are needed to confirm and further extend the present results.
Authors: Sherine F Elsawa; Anne J Novak; Deanna M Grote; Steven C Ziesmer; Thomas E Witzig; Robert A Kyle; Stacey R Dillon; Brandon Harder; Jane A Gross; Stephen M Ansell Journal: Blood Date: 2005-11-22 Impact factor: 22.113
Authors: Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel Journal: Blood Date: 2006-06-27 Impact factor: 22.113
Authors: Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell Journal: Blood Date: 2011-09-14 Impact factor: 22.113
Authors: B C Potts; M X Albitar; K C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; A Younes; M A Palladino Journal: Curr Cancer Drug Targets Date: 2011-03 Impact factor: 3.428
Authors: David A Jackson; Timothy D Smith; Nansalmaa Amarsaikhan; Weiguo Han; Matthew S Neil; Shannon K Boi; Anne M Vrabel; Ezequiel J Tolosa; Luciana L Almada; Martin E Fernandez-Zapico; Sherine F Elsawa Journal: J Immunol Date: 2015-08-03 Impact factor: 5.422
Authors: Aldo M Roccaro; Xavier Leleu; Antonio Sacco; Xiaoying Jia; Molly Melhem; Anne-Sophie Moreau; Hai T Ngo; Judith Runnels; Abdelkareem Azab; Feda Azab; Nicholas Burwick; Mena Farag; Steven P Treon; Michael A Palladino; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson; Irene M Ghobrial Journal: Blood Date: 2008-03-03 Impact factor: 22.113
Authors: Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial Journal: Cancer Lett Date: 2008-06-13 Impact factor: 8.679
Authors: Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell Journal: Blood Adv Date: 2018-08-14